RT info:eu-repo/semantics/article
T1 Effect of comorbidities and multimorbidity on bone mineral density in patients with osteoporosis
A1 Leal Vega, Luis
A1 Coco Martín, María Begoña
A1 Martín Gutierrez, Adrián
A1 Blázquez Cabrera, José Antonio
A1 Arranz García, Francisca
A1 Navarro, Amalia
A1 Moro, María Jesús
A1 Filgueira, José
A1 Sosa Henríquez, Manuel
A1 Vázquez, María Ángeles
A1 Montoya, María José
A1 Díaz Curiel, Manuel
A1 Olmos, José Manuel
A1 Pérez Castrillon, José Luis
K1 Osteoporosis
K1 Comorbilidad
K1 Multimorbilidad
K1 Densidad ósea
K1 Absorciometría de rayos X de energía dual
K1 Práctica basada en la evidencia
AB SummaryThis retrospective cohort study analysed a total of 344 patients from the OSTEOMED registry with matched baseline and follow-up DXA data, finding that comorbidities such as nephrolithiasis, hypertension or coronary heart disease may influence the response to prescribed anti-osteoporotic treatment.PurposeTo determine: 1) comorbidities associated with reduced bone mineral density (BMD), T-score and Z-score at the lumbar spine (L1 to L4 vertebrae), femoral neck and total hip; and 2) the role of multimorbidity (≥ 2 comorbidities) in reduced BMD, T-score and Z-score at the lumbar spine, femoral neck and total hip.MethodsRetrospective cohort study analyzing patients [319 females (92.73%), 25 males (7.27%), age 62.13 ± 10.46 years] from the OSTEOMED registry with matched baseline and follow-up dual-energy X-ray absorptiometry (DXA) data. Patients' sex, age, body mass index (BMI), comorbidities and treatments were collected from their medical records after they had given written informed consent.ResultsConsidering a least significant change (LSC) of 4.2%, neither comorbidity nor multimorbidity was statistically significantly associated with a reduction in BMD in any of the bone regions studied. However, binary logistic regression analyses adjusted for sex, age, BMI and treatments showed that nephrolithiasis (p = 0.044) and coronary heart disease (p = 0.026) were statistically significantly associated with a reduction in total hip T-score and that hypertension (p = 0.049) and coronary heart disease (p = 0.01) were statistically significantly associated with a reduction in total hip Z-score.ConclusionDespite comorbidity and multimorbidity, patients with osteoporosis are mostly well protected by anti-osteoporotic treatment in daily clinical practice. However, nephrolithiasis, hypertension, and coronary heart disease can influence the response to prescribed anti-osteoporotic treatment, especially at the total hip level.
PB Springer Nature
YR 2025
FD 2025
LK https://uvadoc.uva.es/handle/10324/79186
UL https://uvadoc.uva.es/handle/10324/79186
LA eng
NO Archives of Osteoporosis, 2025, vol. 20, n. 121.
NO Producción Científica
DS UVaDOC
RD 27-nov-2025